Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in CD30-positive mature T-cell lymphomas
NCT01777152Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Jan 2013
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of brentuximab vedotin in mature T-cell lymphoma (PTCL), sponsored by Seagen Inc.. Started Jan 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
mature T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT01777152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777152.